Sutro Biopharma Inc [STRO] stock is trading at $1.01, up 14.68%. An important factor to consider is whether the stock is rising or falling in short-term value. The STRO shares have gain 25.67% over the last week, with a monthly amount glided 11.87%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Sutro Biopharma Inc [NASDAQ: STRO] stock has seen the most recent analyst activity on June 16, 2025, when Piper Sandler upgraded its rating to a Overweight but kept the price target unchanged to $2 for it. Previously, H.C. Wainwright downgraded its rating to Neutral on March 17, 2025. On March 14, 2025, downgrade downgraded it’s rating to Neutral and revised its price target to $2 on the stock. Citizens JMP downgraded its rating to a Mkt Perform. BofA Securities downgraded its rating to a Underperform and reduced its price target to $1 on March 14, 2025. BofA Securities started tracking with a Buy rating for this stock on May 08, 2024, and assigned it a price target of $12. In a note dated November 09, 2023, Deutsche Bank initiated an Buy rating and provided a target price of $12 on this stock.
Sutro Biopharma Inc [STRO] stock has fluctuated between $0.52 and $4.60 over the past year. Currently, Wall Street analysts expect the stock to reach $9.86 within the next 12 months. Sutro Biopharma Inc [NASDAQ: STRO] shares were valued at $1.01 at the most recent close of the market. An investor can expect a potential return of 876.24% based on the average STRO price forecast.
Analyzing the STRO fundamentals
Sutro Biopharma Inc [NASDAQ:STRO] reported sales of 104.47M for the trailing twelve months, which represents a growth of 147.98%. Gross Profit Margin for this corporation currently stands at 0.96% with Operating Profit Margin at -1.96%, Pretax Profit Margin comes in at -1.98%, and Net Profit Margin reading is -2.0%. To continue investigating profitability, this company’s Return on Assets is posted at -0.8, Equity is -8.53 and Total Capital is -1.09. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-0.61.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.9133 points at the first support level, and at 0.8167 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.1133, and for the 2nd resistance point, it is at 1.2167.
Ratios To Look Out For
For context, Sutro Biopharma Inc’s Current Ratio is 3.12. On the other hand, the Quick Ratio is 3.12, and the Cash Ratio is 0.86. Considering the valuation of this stock, the price to sales ratio is 0.82.
Transactions by insiders
Recent insider trading involved Gerber Hans-Peter, CHIEF SCIENTIFIC OFFICER, that happened on Oct 15 ’25 when 17000.0 shares were purchased. CFO, Chow Gregory K. completed a deal on Oct 15 ’25 to buy 19750.0 shares. Meanwhile, Chief Executive Officer Chung Jane bought 12500.0 shares on Oct 15 ’25.
